Evidence map›Paper›PMID 33570497›Full record

Trial reportJMIR mHealth and uHealth2021

An Interactive Voice Response Software to Improve the Quality of Life of People Living With HIV in Uganda: Randomized Controlled Trial.

Dathan Mirembe Byonanebye, Maria S Nabaggala, Agnes Bwanika Naggirinya, Mohammed Lamorde, Elizabeth Oseku, Rachel King, Noela Owarwo, Eva Laker, Richard Orama, Barbara Castelnuovo and 2 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JMIR mHealth and uHealth, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02953080 (Improving Outcomes in HIV Patients Using Mobile Phone Based Interactive Software Support), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02953080 nacompletednot on this map

Improving Outcomes in HIV Patients Using Mobile Phone Based Interactive Software Support

TypeinterventionalSponsorMakerere UniversityRan2016 to 2018Enrolled600ConditionsHuman Immunodeficiency VirusArmsCall for life mHealth adherence support
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Dathan Mirembe ByonanebyeDepartment of Community Health and Behavioural Sciences, Makerere University School of Public Health, Makerere University, Kampala, Uganda.ORCID 0000-0001-9862-4724
Maria S NabaggalaInfectious Diseases Institute, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0002-1630-9104
Agnes Bwanika NaggirinyaThe Academy for Health Innovations, Infectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID 0000-0001-8722-4135
Mohammed LamordeInfectious Diseases Institute, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0003-2218-6822
Elizabeth OsekuThe Academy for Health Innovations, Infectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID 0000-0002-0049-3787
Rachel KingThe Academy for Health Innovations, Infectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID 0000-0002-0085-3498
Noela OwarwoInfectious Diseases Institute, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0002-3455-2116
Eva LakerInfectious Diseases Institute, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0002-7937-1538
Richard OramaInfectious Diseases Institute, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0001-9212-7890
Barbara CastelnuovoInfectious Diseases Institute, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0001-7756-5032
Agnes KiraggaInfectious Diseases Institute, Makerere University College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0002-0969-0699
Rosalind Parkes-RatanshiThe Academy for Health Innovations, Infectious Diseases Institute, Makerere University, Kampala, Uganda.ORCID 0000-0001-9297-1311
Infectious Diseases Institute · UGUniversity of Cambridge · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFollowing the successful scale-up of antiretroviral therapy (ART), the focus is now on ensuring good quality of life (QoL) and sustained viral suppression in people living with HIV. The access to mobile technology in the most burdened countries is increasing rapidly, and therefore, mobile health (mHealth) technologies could be leveraged to improve QoL in people living with HIV. However, data on the impact of mHealth tools on the QoL in people living with HIV are limited to the evaluation of SMS text messaging; these are infeasible in high-illiteracy settings.

objectiveThe primary and secondary outcomes were to determine the impact of interactive voice response (IVR) technology on Medical Outcomes Study HIV QoL scores and viral suppression at 12 months, respectively.

methodsWithin the Call for Life study, ART-experienced and ART-naïve people living with HIV commencing ART were randomized (1:1 ratio) to the control (no IVR support) or intervention arm (daily adherence and pre-appointment reminders, health information tips, and option to report symptoms). The software evaluated was Call for Life Uganda, an IVR technology that is based on the Mobile Technology for Community Health open-source software. Eligibility criteria for participation included access to a phone, fluency in local languages, and provision of consent. The differences in differences (DIDs) were computed, adjusting for baseline HIV RNA and CD4.

resultsOverall, 600 participants (413 female, 68.8%) were enrolled and followed-up for 12 months. In the intervention arm of 300 participants, 298 (99.3%) opted for IVR and 2 (0.7%) chose SMS text messaging as the mode of receiving reminders and health tips. At 12 months, there was no overall difference in the QoL between the intervention and control arms (DID=0.0; P=.99) or HIV RNA (DID=0.01; P=.94). At 12 months, 124 of the 256 (48.4%) active participants had picked up at least 50% of the calls. In the active intervention participants, high users (received >75% of reminders) had overall higher QoL compared to low users (received <25% of reminders) (92.2 versus 87.8, P=.02). Similarly, high users also had higher QoL scores in the mental health domain (93.1 versus 86.8, P=.008) and better appointment keeping. Similarly, participants with moderate use (51%-75%) had better viral suppression at 12 months (80/94, 85% versus 11/19, 58%, P=.006).

conclusionsOverall, there was high uptake and acceptability of the IVR tool. While we found no overall difference in the QoL and viral suppression between study arms, people living with HIV with higher usage of the tool showed greater improvements in QoL, viral suppression, and appointment keeping. With the declining resources available to HIV programs and the increasing number of people living with HIV accessing ART, IVR technology could be used to support patient care. The tool may be helpful in situations where physical consultations are infeasible, including the current COVID epidemic.

trial registrationClinicalTrials.gov NCT02953080; https://clinicaltrials.gov/ct2/show/NCT02953080.

Indexed as

COVID-19HIV InfectionsFemaleHumansQuality of LifeSARS-CoV-2SoftwareUgandadigital healthHIVinteractive voice responsemHealthmobile healthquality of life

Identifiers

PMID33570497
PMCPMC7906832
OpenAlexW3119711028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.